Document Classification

Section Type: RESULTS

Text: The percentage of patients who showed an increase in posterior RNP from baseline increased over time in all 3 groups, but at a faster rate in the sham group, resulting in statistically significant differences at every time point between months 3 (9. 6 % vs. 18. 5 % ; P = 0. 016) and 24 (16. 1 % vs. 37. 6 % ; P < 0. 0001) for ranibizumab 0. 5 mg versus sham and from months 6 (12. 3 % vs. 23. 0 % ; P = 0. 013) through 24 (15. 0 % vs. 37. 6 % ; P < 0. 0001) for ranibizumab 0. 3 mg.